ライフサイエンスコーパス: beta-adrenergic blocking agent

1 ideline-recommended medications (aspirin and beta-adrenergic blocking agents).

2 t with either alpha-2 adrenergic agonists or beta adrenergic blocking agents.

3 treating chronic heart failure patients with beta-adrenergic blocking agents.

4 not differ between the investigated types of beta-adrenergic blocking agents.

5 ncluded; seven patients (41%) were receiving beta-adrenergic blocking agents.

6 ats/min, p < 0.0001) and more often received beta-adrenergic blocking agents (49% vs. 14%, p < 0.0001

7 Beta-adrenergic blocking agents (abbreviated as beta-blo

8 However, for the subset of patients on beta-adrenergic blocking agents after CABG, there was a

9 ed long-term health outcomes associated with beta-adrenergic blocking agents and diltiazem treatment

10 omen; mean age 57 years) who were not taking beta-adrenergic blocking agents and were referred for sy

11 inical Question: Does nurse-led titration of beta-adrenergic blocking agents, angiotensin-converting

12 The use of aspirin, beta-adrenergic blocking agents, angiotensin-converting

13 pitals with such capability when aspirin and beta-adrenergic blocking agents are given appropriately

14 Beta-adrenergic blocking agents are used in most patient

15 al treatments for patients with AMI, such as beta-adrenergic blocking agents, aspirin and immediate r

16 sease or the use of concomitant medications (beta-adrenergic blocking agents, calcium channel blockin

17 lysis of several studies with the alpha- and beta-adrenergic blocking agent carvedilol demonstrated a

18 n include initial therapy with a diuretic or beta-adrenergic blocking agent, for which reductions in

19 Chronic treatment with beta-adrenergic blocking agents has been shown to improv

20 Beta-adrenergic blocking agents have been revalidated in

21 ey were also more likely to receive aspirin, beta-adrenergic blocking agents, heparin and nitrates (a

22 ven medications such as aspirin, statins and beta-adrenergic blocking agents in conjunction with comp

23 sure in cardiomyopathy patients treated with beta-adrenergic blocking agents is controversial.

24 udy was designed to examine the effects of a beta-adrenergic blocking agent on the ischemic response

25 ensin-converting enzyme (ACE) inhibitors and beta-adrenergic blocking agents on the remodeling proces

26 ents with stable angina pectoris receiving a beta-adrenergic blocking agent or calcium antagonist, or

27 treatment with either timolol, a nonspecific beta adrenergic blocking agent, or with para-aminoclonid

28 lations: patients with first MI, patients on beta-adrenergic blocking agents, patients with LVEF < or

29 ver, group 1 patients had significantly less beta-adrenergic blocking agent use and higher ejection f

30 his analysis was performed to assess whether beta-adrenergic blocking agent use is associated with re

31 ox multivariate analysis, the association of beta-adrenergic blocking agent use with reduced mortalit

32 atients; After adjusting for age, gender and beta-adrenergic blocking agent use, multiple logistic re

33 inversely to prior myocardial infarction and beta-adrenergic blocking agent use.

34 Beta-adrenergic blocking agents were administered concur

35 Angiotensin-converting-enzyme inhibitors and beta-adrenergic-blocking agents were administered if the

36 Sotalol, a beta-adrenergic blocking agent with class III antiarrhyt